Gary Raskob to Drug Administration Schedule
This is a "connection" page, showing publications Gary Raskob has written about Drug Administration Schedule.
Connection Strength
1.148
-
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 11; 17(11):1866-1874.
Score: 0.161
-
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016 06 02; 115(6):1240-8.
Score: 0.126
-
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost. 2014 Jun; 12(6):824-30.
Score: 0.113
-
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013 Jul; 11(7):1287-94.
Score: 0.106
-
Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012 Feb; 94(2):257-64.
Score: 0.096
-
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9.
Score: 0.086
-
Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med. 2007 Sep 13; 357(11):1105-12.
Score: 0.071
-
Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003 Dec; 124(6 Suppl):379S-385S.
Score: 0.054
-
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001 Sep 10; 161(16):1952-60.
Score: 0.047
-
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar; 119(3):461-466.
Score: 0.039
-
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
Score: 0.039
-
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127.
Score: 0.038
-
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10; 369(15):1406-15.
Score: 0.027
-
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013 Mar; 11(3):444-51.
Score: 0.026
-
Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011 May 24; 342:d3036.
Score: 0.023
-
Duration of warfarin in pulmonary embolism. Chest. 2006 Jul; 130(1):299; author reply 299-300.
Score: 0.016
-
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004 Jun 01; 140(11):867-73.
Score: 0.014
-
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003 Oct 30; 349(18):1695-702.
Score: 0.014
-
The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998 Jan 01; 128(1):1-7.
Score: 0.009
-
Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med. 1997 Dec 8-22; 157(22):2562-8.
Score: 0.009
-
The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med. 1997 Nov 10; 157(20):2317-21.
Score: 0.009
-
Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):289-94.
Score: 0.008
-
Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1994 Oct 01; 74(7):657-61.
Score: 0.007
-
Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med. 1994 May 09; 154(9):999-1004.
Score: 0.007
-
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990 May 03; 322(18):1260-4.
Score: 0.005